Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from DSMB

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation for Intellia Therapeutics’ (NASDAQ:NTLA) lead asset NTLA-2002, for the treatment of hereditary angioedema (HAE). Intellia shares traded in a range of $56.52 to $60.06 on day volume of 901.43 thousand shares, closed regular trading session at $59.97. The company…

CFRX: DSMB Recommends DISRUPT Study be Stopped for Futility…

Bautz: By David Bautz, PhD NASDAQ:CFRX READ THE FULL CFRX RESEARCH REPORT

Revive Therapeutics: Positive Comments From The FDA Regarding Primary Endpoint Change

Revive Therapeutics: Positive Comments From The FDA Regarding Primary Endpoint Change

The outlook for Revive Therapeutics Ltd. (OTC: RVVTF) Phase 3 clinical trial to evaluate the safety and efficacy of Bucillamine to treat COVID-19 got a little brighter on Thursday.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Why NRX Pharmaceuticals Shares Are Trading Lower During Premarket On Thursday?

Based on the review of approximately 460 patients, Data Safety and Monitoring Board (DSMB) determined that the evaluation of NRx Pharmaceuticals Inc's (NASDAQ:NRXP) Zyesami (aviptadil) should cease due to futility. Aviptadil was the sole remaining investigational medicine in ACTIV-3b targeted at critical-ill COVID-19 patients. ACTIV-3b study evaluated Zyesami and Gilead Sciences Inc's (NASDAQ:GILD) Veklury (remdesivir)…

EDSA: Enrollment of Phase 2b Trial of EB01 to Complete in 4Q22…

By David Bautz, PhD NASDAQ:EDSA READ THE FULL EDSA RESEARCH REPORT

Why PolyPid Shares Are Gaining Today

The independent Data Safety Monitoring Board (DSMB) has recommended concluding enrollment in PolyPid Ltd's (NASDAQ:PYPD) SHIELD I Phase 3 study of D-PLEX100 to prevent surgical site infections (SSIs) abdominal tissue surgery. DSMB recommended stopping enrollment upon 950 patients, which is the minimum number of targeted patients in the study protocol The suggestion follows the…

Details Of Revive Therapeutics' Update On Bucillamine Phase 3 Trial For COVID Treatment

Revive Therapeutics (OTC: RVVTF) has provided an update on Phase 3 of its Buc

inkl

Read news from The Economist, FT, and more,
with one subscription

CLSN: DSMB Recommends Continuing to Dose Patients in OVATION 2 Study…

By David Bautz, PhD NASDAQ:CLSN READ THE FULL CLSN RESEARCH REPORT

Why Are Allena Pharma Shares Plunging Today

Why Are Allena Pharma Shares Plunging Today

An independent data safety monitoring board (DSMB) has conducted the first of two planned Sample Size Reestimations (SSR1) of

EDSA: Phase 3 Trial of EB05 Hits 25% Enrollment…

By David Bautz, PhD NASDAQ:EDSA READ THE FULL EDSA RESEARCH REPORT

Safety Board Recommends BioCardia's Heart Failure Cell Therapy To Continue Unchanged

Safety Board Recommends BioCardia's Heart Failure Cell Therapy To Continue Unchanged

The independent Data Safety Monitoring Board (DSMB) has completed its prespecified data review for&

1

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Gilead Sciences Inc

European Medicines Agency

National Institutes of Health

National Institute of Allergy and Infectious Diseases

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Pulmonary Fibrosis

Places

231,010 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play